deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03421288

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (DANTE)

A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340) - The IKF-DANTE Trial

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Conditions Gastric Cancer Gastroesophageal Junction Adenocarcinoma
Interventions 5-Fluorouracil Atezolizumab Calciumfolinat Docetaxel Oxaliplatin
Updated 16 times since 2018 Last updated: Jul 22, 2025 Started: Sep 14, 2018 Primary completion: May 31, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, this trial is ongoing. The trial is conducted by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest and has accumulated 16 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Apr 2020 · 10 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshot~May 2022 – ~Sep 2023 · 16 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

16 versions recorded

  1. Aug 2025 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Aug 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Sep 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  5. May 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. May 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  6. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  7. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  8. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jul 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE2

  11. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
  • Roche Pharma AG
Data source: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations